Invivoscribe Submits Pre-Market Approval Application in Japan and Panel Track Supplement in the US to Screen Acute Myeloid Leukemia (AML) Patients for FLT3 Mutations
⟵ PRESS RELEASES PRESS RELEASE SAN DIEGO, [...]
Invivoscribe® Releases LeukoStrat® CDx FLT3 Mutation Assay as CE-marked IVD Assay Kit.
⟵ PRESS RELEASES PRESS RELEASE SAN DIEGO, [...]
Invivoscribe Expands Long-Term Collaboration Agreement to Release FLT3 Mutation and Clonality Assay Kits
⟵ PRESS RELEASES PRESS RELEASE SAN DIEGO, [...]
Novartis drug PKC412 (midostaurin) granted FDA Priority Review for newly-diagnosed FLT3-mutated AML and advanced systemic mastocytosis
⟵ PRESS RELEASES PRESS RELEASE Basel - [...]
German Supreme Court Upholds and Strengthens Invivoscribe FLT3 Patent Position
⟵ PRESS RELEASES PRESS RELEASE SAN DIEGO, [...]
Novartis drug PKC412 (midostaurin) receives Breakthrough Therapy designation from the FDA for newly-diagnosed FLT3-mutated acute myeloid leukemia (AML)
⟵ PRESS RELEASES PRESS RELEASE Basel - [...]
Novartis drug PKC412 (midostaurin) improves overall survival by 23% in global Phase III study of AML patients with FLT3 mutations
⟵ PRESS RELEASES PRESS RELEASE EAST HANOVER, [...]